The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 75.00
Bid: 70.00
Ask: 80.00
Change: -2.50 (-3.23%)
Spread: 10.00 (14.286%)
Open: 77.50
High: 77.50
Low: 75.00
Prev. Close: 77.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close Trading Statement

23 Jan 2013 07:00

RNS Number : 1409W
Biome Technologies PLC
23 January 2013
 



23 January 2013

 

Biome Technologies plc

 

("Biome" or "the Group")

 

Pre-close Trading Statement

 

Biome Technologies plc, the bioplastics and RF technology business, is pleased to provide a pre-close trading statement for the financial year ended 31 December 2012 ahead of the announcement of the audited Preliminary Results, which are scheduled to be published on 27 March 2013.

 

The Board reports that it expects the financial performance of Biome for the full year period to be in line with its expectations. As announced in the Group's most recent trading update, following the sale of its 50% share in Biotec Holding GmbH ("Biotec") in October 2012 for £5.2m, the Board is assessing various options to accelerate the development strategy of the Group and expects to provide a fuller update at the Preliminary Results.

 

Following the successful sale of Biotec, Biome is now able to focus on the commercialisation and development of its 100% owned intellectual property in the area of premium products. Biome began this work in 2008 and is now involved with a number of interesting customer opportunities with significant market potential. These include the pre-launch evaluation work with a leading manufacturer of high performance single-use foodservice products and the launch of multi-layer sealing film for single-use coffee capsules. The former project is progressing well and the latter was market tested in the fourth quarter of 2012 with a full launch now underway in January 2013 with some 40 tonnes delivered already. While the expected growth trajectories of both of these applications are potentially strong, their actual performance will be clearer by the second half of 2013.

 

Biome is also investigating opportunities for the manufacture of bio-based materials through the use of synthetic biology. This is an emerging technology and Biome has a small number of early stage collaborations with both academic and industrial partners. The UK Government has identified the commercialisation of synthetic biology as an area of high priority where the UK can build a world leading position. The Board is exploring opportunities to accelerate the position of the business in this area in 2013 using mainly its intellectual, rather than its cash assets. To further this objective the business has an application for funding under consideration by the Technology Strategy Board (a Government body charged with making the UK a global leader in innovation) to support its research in this field.

 

The Stanelco RF Technologies team continues to explore opportunities to accelerate the expansion of the division and has a developing order book for the first half of 2013. This follows a slightly subdued end to 2012 as a number of optical fibre furnace deliveries were delayed due to some turbulence in the Chinese fibre market. Good progress continues on the Durapipe project and delivery timing for ten pre-production units is being finalised. The business has recently been appointed as the UK sales and service agent for Forsstrom High Frequency AB ("Forsstrom"). Forsstrom is a world leading supplier of High Frequency welding equipment and this agreement extends Stanelco's product offering into larger welding equipment.

 

The Group continues to challenge all aspects of its cost base. The legacy long leases on buildings in Southampton remain a significant drag on the path towards profitability and the Board is exploring a number of strategies that might mitigate this outflow.

 

As outlined previously, the Board is giving consideration to returning funds from the sale of Biotec to shareholders that may be in excess of those required in the medium term. As this would require a re-organisation of capital, given the large accumulated losses and substantial share premium accounts, the Board is examining all the issues relevant to that and expects to update shareholders at the Preliminary results.

 

The Group's existing debt facility has remained unutilised for some time. Given current cash balances and working capital needs, this facility was terminated on 22 January and will result in modest future cost savings. The Group's cash position at 31 December 2012 was up significantly to £6.3m (UK cash position 30 September 2012: £1.3m).

 

-Ends-

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

 

Daniel Stewart & Company plc

David Hart

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVLLFLXFFXBBD
Date   Source Headline
29th Apr 20247:01 amRNSTrading Update
29th Apr 20247:00 amRNSFinal Results 2023
15th Mar 20247:00 amRNSContract win for Stanelco RF Division
11th Mar 20241:59 pmRNSIssue of Convertible Loan Notes, PDMR Notification
15th Feb 20242:54 pmRNSContract win for RF Division
6th Feb 20247:00 amRNSTrading Update
13th Nov 20237:00 amRNSTrading Update
10th Oct 20234:32 pmRNSGrant of Options
27th Sep 20237:00 amRNSInterim Results
26th Jul 20237:00 amRNSTrading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20237:00 amRNSContract win for Stanelco RF Division
31st May 20237:00 amRNSIssue of Equity, Director/PDMR Shareholding & TVR
25th May 20232:57 pmRNSAppointment of Non-Executive Director
25th May 202312:45 pmRNSResult of AGM
2nd May 20231:05 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSNotice of AGM and 2022 Annual Report
26th Apr 20237:01 amRNSTrading Update
26th Apr 20237:00 amRNSFinal Results 2022
18th Apr 202310:49 amRNSCompletion of CLN Fundraising
17th Apr 202311:30 amRNSResult of General Meeting
31st Mar 202311:14 amRNSProposed issue of Convertible Loan Notes
25th Jan 20237:00 amRNSTrading Update
16th Nov 20227:00 amRNSBiome receives £282k grant
10th Nov 202211:05 amRNSSecond Price Monitoring Extn
10th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSTrading Update
18th Oct 20229:28 amRNSHolding(s) in Company
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results
5th Sep 20227:00 amRNSGrant funding from Innovate UK
2nd Aug 20228:59 amRNSTrading Update - Replacement
2nd Aug 20227:00 amRNSTrading Update
20th Apr 202212:01 pmRNSResult of Annual General Meeting
20th Apr 20227:00 amRNSTrading Update
30th Mar 20222:48 pmRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSNotice of AGM and 2021 Annual Report
24th Mar 20227:00 amRNSFinal Results 2021
27th Jan 20227:00 amRNSTrading Update
4th Jan 202210:33 amRNSFurther substantial contract win for RF Division
16th Dec 20218:41 amRNSContract
17th Nov 20217:00 amRNSTrading Update
9th Nov 202111:12 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSUpdate re biodegradable tree shelters
15th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.